Orexigen Therapeutics, Inc. (OREX) Posts Q4 Loss of 9c/Share
Get Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $940 thousand.
For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.
For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- RF Industries (RFIL) Misses Q1 EPS by 12c
- Peraso Inc. (PRSO) Misses Q4 EPS by 844c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!